Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $975.00 Price Target at Guggenheim

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price raised by Guggenheim from $865.00 to $975.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

REGN has been the topic of a number of other reports. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. JPMorgan Chase & Co. increased their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Royal Bank Of Canada lifted their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 29th. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Finally, Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $793.81.

Regeneron Pharmaceuticals Stock Down 0.7%

Shares of NASDAQ:REGN opened at $780.28 on Monday. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11. The firm has a fifty day moving average of $757.89 and a 200 day moving average of $660.34. The firm has a market capitalization of $82.01 billion, a PE ratio of 18.77, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the business posted $12.07 earnings per share. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.47%.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 7.02% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several large investors have recently modified their holdings of the business. Osaic Holdings Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 55.2% during the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after purchasing an additional 6,073 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its position in Regeneron Pharmaceuticals by 153.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after purchasing an additional 73,176 shares during the period. PGGM Investments raised its stake in Regeneron Pharmaceuticals by 9.7% during the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock valued at $52,057,000 after buying an additional 8,187 shares during the last quarter. Bellecapital International Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 32.7% during the 2nd quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock valued at $13,389,000 after buying an additional 6,283 shares during the period. Finally, Rakuten Investment Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $33,121,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.